RAKOVINA THERAPEUTICS INC (RKV.CA)
CA75103L1013 - Common Stock
Rakovina Therapeutics: Reflecting on 2024 Success and Building Momentum for a Transformative 2025
VANCOUVER, British Columbia, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) a biopharmaceutical...
Rakovina Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) announces that in...
Rakovina Therapeutics Announces Closing of Oversubscribed $3M Private Placement
VANCOUVER, British Columbia, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”, “Rakovina”, or “Rakovina...
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit
VANCOUVER, British Columbia, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical...
Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million
VANCOUVER, British Columbia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a...
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated...
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million
VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a...
Rakovina Therapeutics Announces Private Placement Offering
The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering...
Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical...
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
VANCOUVER, British Columbia, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical...
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain
VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical...
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform
Company to present initial results of this research at the Society for Neuro-Oncology Annual Meeting in November...
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer...
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Rakovina...
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
All dollar amounts reflected in Canadian dollars unless otherwise stated....
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 22, 2024 (GLOBE NEWSWIRE) -- Rakovina...
Rakovina Therapeutics Announces Second Upsizing of Private Placement
All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 19, 2024 (GLOBE NEWSWIRE) -- Rakovina...
Rakovina Therapeutics Announces Oversubscribed Private Placement and Results from 2024 Annual General Meeting
All dollar amounts reflected in Canadian dollars unless otherwise stated...
Rakovina Therapeutics Announces 2024 Q1 Financial Results and Provides Corporate Update
All dollar amounts reflected in Canadian dollars unless otherwise stated...
Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 24, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina”...
Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV,...
Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research
Expanded Activities Position Rakovina Therapeutics to Capitalize on AI Partnerships with The University of British Columbia and Pharma Inventor Inc....
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company...
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a...
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
Announces Capital Markets Advisory Agreement...
Rakovina Therapeutics Announces Strategic Pivot to AI
Company Leveraging Deep Docking AI Drug Discovery Platform
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company...
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company...
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company...
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company...
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company...
Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) is pleased to...
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company...
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of...
Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is pleased to...
Rakovina Therapeutics Inc. Announces Enhanced Liquidity and Investor Awareness Programs
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the engagement of...
Rakovina Therapeutics Receives Funding to Accelerate Development of Novel Cancer Therapies
VANCOUVER, British Columbia, March 22, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (“the Company”), is pleased to announce that it is...
Rakovina Therapeutics Inc. Announces Plan to Apply to Extend Warrant Expiry Dates
VANCOUVER, British Columbia, March 10, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) announces that it may apply to the...
Rakovina Therapeutics Announces Presentation at the 6th Annual DDR-inhibitors Summit
VANCOUVER, British Columbia, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), is pleased to announce a...
Rakovina Therapeutics to Present at the Emerging Growth Conference on November 30, 2022
VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical...